Dokumentvorlage, Version vom 16.12.2021

Dossier zur Nutzenbewertung gemäß § 35a SGB V

Pembrolizumab (KEYTRUDA®)

MSD Sharp & Dohme GmbH

Modul 4 D

Behandlung von Tumoren mit MSI-H oder mit einer dMMR bei Erwachsenen: Nicht resezierbares oder metastasierendes Dünndarmkarzinom

Medizinischer Nutzen und
medizinischer Zusatznutzen,
Patientengruppen mit therapeutisch
bedeutsamem Zusatznutzen

Stand: 18.07.2022

Inhaltsverzeichnis

Seite

Tabellenverzeichnis

Seite

Anhang 4-G: Weitere Ergebnisse

Anhang 4-G1: Rücklaufquoten des EORTC QLQ-C30 und EQ-5D VAS

Im Folgenden werden ergänzend zu Abschnitt 4.3.2.3.3.2.1 die Rücklaufquoten des EORTC QLQ-C30 und die Rücklaufquoten des EQ-5D VAS dargestellt.

Alle Ergebnisse beziehen sich auf den Datenschnitt vom 05. Oktober 2020.

Anhang 4-G1.1: Rücklaufquoten des EORTC QLQ-C30

Tabelle 4G-1: Gründe für das Fehlen von Werten im EORTC QLQ-C30

Study: KEYNOTE 158[a]		**Pembrolizumab**
Visit	**EORTC QLQ-C30**	**N[b] = 25 n (%)**
Baseline	Missing by Design	0 (0.0)
	Discontinued due to adverse event	0 (0.0)
	Discontinued due to clinical progression	0 (0.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	0 (0.0)
	Discontinued due to withdrawal by subject	0 (0.0)
	Completed study treatment	0 (0.0)
	Visit not reached	0 (0.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	25 (100.0)
	Not completed	2 (8.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	0 (0.0)
	With visit, no record	2 (8.0)
	Completed	23 (92.0)
	Compliance (% in those expected to complete questionnaires)[d]	23 (92.0)
Week 3	Missing by Design	1 (4.0)
	Discontinued due to adverse event	0 (0.0)
	Discontinued due to clinical progression	0 (0.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	0 (0.0)
	Discontinued due to withdrawal by subject	0 (0.0)
	Completed study treatment	0 (0.0)
	Visit not reached	0 (0.0)
	Visit not scheduled	1 (4.0)
	Expected to Complete Questionnaires[c]	24 (96.0)
	Not completed	3 (12.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	1 (4.0)
	Subject refused for other reasons	0 (0.0)
	Other	1 (4.0)
	With visit, no record	1 (4.0)
	Completed	21 (84.0)
	Compliance (% in those expected to complete questionnaires)[d]	21 (87.5)
Week 6	Missing by Design	1 (4.0)
	Discontinued due to adverse event	0 (0.0)
	Discontinued due to clinical progression	0 (0.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	0 (0.0)
	Discontinued due to withdrawal by subject	0 (0.0)
	Completed study treatment	0 (0.0)
	Visit not reached	1 (4.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	24 (96.0)

Study: KEYNOTE 158[a]		**Pembrolizumab**
Visit	**EORTC QLQ-C30**	**N**[b] **= 25** **n (%)**
	Not completed	1 (4.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	0 (0.0)
	With visit, no record	1 (4.0)
	Completed	23 (92.0)
	Compliance (% in those expected to complete questionnaires)[d]	23 (95.8)
Week 9	Missing by Design	1 (4.0)
	Discontinued due to adverse event	0 (0.0)
	Discontinued due to clinical progression	0 (0.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	0 (0.0)
	Discontinued due to withdrawal by subject	0 (0.0)
	Completed study treatment	0 (0.0)
	Visit not reached	1 (4.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	24 (96.0)
	Not completed	1 (4.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	0 (0.0)
	With visit, no record	1 (4.0)
	Completed	23 (92.0)
	Compliance (% in those expected to complete questionnaires)[d]	23 (95.8)
Week 18	Missing by Design	2 (8.0)
	Discontinued due to adverse event	0 (0.0)
	Discontinued due to clinical progression	0 (0.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	1 (4.0)
	Discontinued due to withdrawal by subject	0 (0.0)
	Completed study treatment	0 (0.0)
	Visit not reached	1 (4.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	23 (92.0)
	Not completed	2 (8.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	1 (4.0)
	With visit, no record	1 (4.0)
	Completed	21 (84.0)
	Compliance (% in those expected to complete questionnaires)[d]	21 (91.3)
Week 27	Missing by Design	3 (12.0)
	Discontinued due to adverse event	0 (0.0)
	Discontinued due to clinical progression	0 (0.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	2 (8.0)
	Discontinued due to withdrawal by subject	0 (0.0)
	Completed study treatment	0 (0.0)
	Visit not reached	1 (4.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	22 (88.0)
	Not completed	4 (16.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	1 (4.0)
	Subject refused for other reasons	0 (0.0)

Study: KEYNOTE 158[a]		**Pembrolizumab**
Visit	**EORTC QLQ-C30**	**N**[b] **= 25** **n (%)**
	Other	1 (4.0)
	With visit, no record	2 (8.0)
	Completed	18 (72.0)
	Compliance (% in those expected to complete questionnaires)[d]	18 (81.8)
Week 39	Missing by Design	6 (24.0)
	Discontinued due to adverse event	0 (0.0)
	Discontinued due to clinical progression	0 (0.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	5 (20.0)
	Discontinued due to withdrawal by subject	0 (0.0)
	Completed study treatment	0 (0.0)
	Visit not reached	1 (4.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	19 (76.0)
	Not completed	5 (20.0)
	Subject did not complete due to disease under study	1 (4.0)
	Not completed due to site staff error	1 (4.0)
	Subject refused for other reasons	1 (4.0)
	Other	0 (0.0)
	With visit, no record	2 (8.0)
	Completed	14 (56.0)
	Compliance (% in those expected to complete questionnaires)[d]	14 (73.7)
Week 51	Missing by Design	10 (40.0)
	Discontinued due to adverse event	1 (4.0)
	Discontinued due to clinical progression	1 (4.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	5 (20.0)
	Discontinued due to withdrawal by subject	1 (4.0)
	Completed study treatment	0 (0.0)
	Visit not reached	2 (8.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	15 (60.0)
	Not completed	3 (12.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	2 (8.0)
	With visit, no record	1 (4.0)
	Completed	12 (48.0)
	Compliance (% in those expected to complete questionnaires)[d]	12 (80.0)
Week 63	Missing by Design	12 (48.0)
	Discontinued due to adverse event	2 (8.0)
	Discontinued due to clinical progression	1 (4.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	5 (20.0)
	Discontinued due to withdrawal by subject	1 (4.0)
	Completed study treatment	0 (0.0)
	Visit not reached	3 (12.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	13 (52.0)
	Not completed	4 (16.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	4 (16.0)
	Subject refused for other reasons	0 (0.0)
	Other	0 (0.0)
	With visit, no record	0 (0.0)
	Completed	9 (36.0)

Study: KEYNOTE 158[a]		**Pembrolizumab**
Visit	**EORTC QLQ-C30**	**N**[b] **= 25** **n (%)**
	Compliance (% in those expected to complete questionnaires)[d]	9 (69.2)
Week 75	Missing by Design	12 (48.0)
	Discontinued due to adverse event	2 (8.0)
	Discontinued due to clinical progression	1 (4.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	5 (20.0)
	Discontinued due to withdrawal by subject	1 (4.0)
	Completed study treatment	0 (0.0)
	Visit not reached	3 (12.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	13 (52.0)
	Not completed	4 (16.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	2 (8.0)
	With visit, no record	2 (8.0)
	Completed	9 (36.0)
	Compliance (% in those expected to complete questionnaires)[d]	9 (69.2)
Week 87	Missing by Design	15 (60.0)
	Discontinued due to adverse event	2 (8.0)
	Discontinued due to clinical progression	1 (4.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	5 (20.0)
	Discontinued due to withdrawal by subject	1 (4.0)
	Completed study treatment	0 (0.0)
	Visit not reached	6 (24.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	10 (40.0)
	Not completed	0 (0.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	0 (0.0)
	With visit, no record	0 (0.0)
	Completed	10 (40.0)
	Compliance (% in those expected to complete questionnaires)[d]	10 (100.0)
Week 99	Missing by Design	16 (64.0)
	Discontinued due to adverse event	2 (8.0)
	Discontinued due to clinical progression	1 (4.0)
	Discontinued due to complete response	1 (4.0)
	Discontinued due to progressive disease	5 (20.0)
	Discontinued due to withdrawal by subject	1 (4.0)
	Completed study treatment	0 (0.0)
	Visit not reached	6 (24.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	9 (36.0)
	Not completed	2 (8.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	1 (4.0)
	Subject refused for other reasons	0 (0.0)
	Other	1 (4.0)
	With visit, no record	0 (0.0)
	Completed	7 (28.0)
	Compliance (% in those expected to complete questionnaires)[d]	7 (77.8)
Week 111	Missing by Design	18 (72.0)
	Discontinued due to adverse event	2 (8.0)

Study: KEYNOTE 158[a]		Pembrolizumab
Visit	EORTC QLQ-C30	N[b] = 25 n (%)
	Discontinued due to clinical progression	1 (4.0)
	Discontinued due to complete response	1 (4.0)
	Discontinued due to progressive disease	5 (20.0)
	Discontinued due to withdrawal by subject	1 (4.0)
	Completed study treatment	2 (8.0)
	Visit not reached	6 (24.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	7 (28.0)
	Not completed	0 (0.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	0 (0.0)
	With visit, no record	0 (0.0)
	Completed	7 (28.0)
	Compliance (% in those expected to complete questionnaires)[d]	7 (100.0)

a: Database Cutoff Date: 05OCT2020
b: Number of participants: full-analysis-set population with MSI-H small intestine carcinoma, at least one line of prior therapy
c: Expected to complete questionnaire includes all participants who do not have missing data due to a missing by design reason
d: Compliance is the proportion of participants who completed the PRO questionnaire among those who are expected to complete the questionnaire at each time point, excluding those missing by design. All the other percentages are defined as the proportion of participants in the analysis population (N)
EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items; MSI-H: Microsatellite Instability-High; PRO: Patient Reported Outcome

Anhang 4-G1.2: Rücklaufquoten des EQ-5D VAS

Tabelle 4G-2: Gründe für das Fehlen von Werten im EQ-5D VAS

Study: KEYNOTE 158[a]		Pembrolizumab
Visit	EQ-5D-3L	N[b] = 25 n (%)
Baseline	Missing by Design	0 (0.0)
	Discontinued due to adverse event	0 (0.0)
	Discontinued due to clinical progression	0 (0.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	0 (0.0)
	Discontinued due to withdrawal by subject	0 (0.0)
	Completed study treatment	0 (0.0)
	Visit not reached	0 (0.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	25 (100.0)
	Not completed	2 (8.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	0 (0.0)
	With visit, no record	2 (8.0)
	Completed	23 (92.0)
	Compliance (% in those expected to complete questionnaires)[d]	23 (92.0)
Week 3	Missing by Design	1 (4.0)
	Discontinued due to adverse event	0 (0.0)
	Discontinued due to clinical progression	0 (0.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	0 (0.0)
	Discontinued due to withdrawal by subject	0 (0.0)

Study: KEYNOTE 158[a]		**Pembrolizumab**
Visit	**EQ-5D-3L**	**N[b] = 25** **n (%)**
	Completed study treatment	0 (0.0)
	Visit not reached	0 (0.0)
	Visit not scheduled	1 (4.0)
	Expected to Complete Questionnaires[c]	24 (96.0)
	Not completed	2 (8.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	1 (4.0)
	With visit, no record	1 (4.0)
	Completed	22 (88.0)
	Compliance (% in those expected to complete questionnaires)[d]	22 (91.7)
Week 6	Missing by Design	1 (4.0)
	Discontinued due to adverse event	0 (0.0)
	Discontinued due to clinical progression	0 (0.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	0 (0.0)
	Discontinued due to withdrawal by subject	0 (0.0)
	Completed study treatment	0 (0.0)
	Visit not reached	1 (4.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	24 (96.0)
	Not completed	1 (4.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	0 (0.0)
	With visit, no record	1 (4.0)
	Completed	23 (92.0)
	Compliance (% in those expected to complete questionnaires)[d]	23 (95.8)
Week 9	Missing by Design	1 (4.0)
	Discontinued due to adverse event	0 (0.0)
	Discontinued due to clinical progression	0 (0.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	0 (0.0)
	Discontinued due to withdrawal by subject	0 (0.0)
	Completed study treatment	0 (0.0)
	Visit not reached	1 (4.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	24 (96.0)
	Not completed	1 (4.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	0 (0.0)
	With visit, no record	1 (4.0)
	Completed	23 (92.0)
	Compliance (% in those expected to complete questionnaires)[d]	23 (95.8)
Week 18	Missing by Design	2 (8.0)
	Discontinued due to adverse event	0 (0.0)
	Discontinued due to clinical progression	0 (0.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	1 (4.0)
	Discontinued due to withdrawal by subject	0 (0.0)
	Completed study treatment	0 (0.0)
	Visit not reached	1 (4.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	23 (92.0)

Study: KEYNOTE 158[a]		**Pembrolizumab**
Visit	**EQ-5D-3L**	**N**[b] **= 25** **n (%)**
	Not completed	2 (8.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	1 (4.0)
	With visit, no record	1 (4.0)
	Completed	21 (84.0)
	Compliance (% in those expected to complete questionnaires)[d]	21 (91.3)
Week 27	Missing by Design	3 (12.0)
	Discontinued due to adverse event	0 (0.0)
	Discontinued due to clinical progression	0 (0.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	2 (8.0)
	Discontinued due to withdrawal by subject	0 (0.0)
	Completed study treatment	0 (0.0)
	Visit not reached	1 (4.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	22 (88.0)
	Not completed	4 (16.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	1 (4.0)
	Subject refused for other reasons	0 (0.0)
	Other	1 (4.0)
	With visit, no record	2 (8.0)
	Completed	18 (72.0)
	Compliance (% in those expected to complete questionnaires)[d]	18 (81.8)
Week 39	Missing by Design	6 (24.0)
	Discontinued due to adverse event	0 (0.0)
	Discontinued due to clinical progression	0 (0.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	5 (20.0)
	Discontinued due to withdrawal by subject	0 (0.0)
	Completed study treatment	0 (0.0)
	Visit not reached	1 (4.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	19 (76.0)
	Not completed	5 (20.0)
	Subject did not complete due to disease under study	1 (4.0)
	Not completed due to site staff error	1 (4.0)
	Subject refused for other reasons	1 (4.0)
	Other	0 (0.0)
	With visit, no record	2 (8.0)
	Completed	14 (56.0)
	Compliance (% in those expected to complete questionnaires)[d]	14 (73.7)
Week 51	Missing by Design	10 (40.0)
	Discontinued due to adverse event	1 (4.0)
	Discontinued due to clinical progression	1 (4.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	5 (20.0)
	Discontinued due to withdrawal by subject	1 (4.0)
	Completed study treatment	0 (0.0)
	Visit not reached	2 (8.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	15 (60.0)
	Not completed	3 (12.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)

Study: KEYNOTE 158[a]		Pembrolizumab
Visit	EQ-5D-3L	N[b] = 25 n (%)
	Other	2 (8.0)
	With visit, no record	1 (4.0)
	Completed	12 (48.0)
	Compliance (% in those expected to complete questionnaires)[d]	12 (80.0)
Week 63	Missing by Design	12 (48.0)
	Discontinued due to adverse event	2 (8.0)
	Discontinued due to clinical progression	1 (4.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	5 (20.0)
	Discontinued due to withdrawal by subject	1 (4.0)
	Completed study treatment	0 (0.0)
	Visit not reached	3 (12.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	13 (52.0)
	Not completed	4 (16.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	4 (16.0)
	Subject refused for other reasons	0 (0.0)
	Other	0 (0.0)
	With visit, no record	0 (0.0)
	Completed	9 (36.0)
	Compliance (% in those expected to complete questionnaires)[d]	9 (69.2)
Week 75	Missing by Design	12 (48.0)
	Discontinued due to adverse event	2 (8.0)
	Discontinued due to clinical progression	1 (4.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	5 (20.0)
	Discontinued due to withdrawal by subject	1 (4.0)
	Completed study treatment	0 (0.0)
	Visit not reached	3 (12.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	13 (52.0)
	Not completed	4 (16.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	2 (8.0)
	With visit, no record	2 (8.0)
	Completed	9 (36.0)
	Compliance (% in those expected to complete questionnaires)[d]	9 (69.2)
Week 87	Missing by Design	15 (60.0)
	Discontinued due to adverse event	2 (8.0)
	Discontinued due to clinical progression	1 (4.0)
	Discontinued due to complete response	0 (0.0)
	Discontinued due to progressive disease	5 (20.0)
	Discontinued due to withdrawal by subject	1 (4.0)
	Completed study treatment	0 (0.0)
	Visit not reached	6 (24.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	10 (40.0)
	Not completed	0 (0.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	0 (0.0)
	With visit, no record	0 (0.0)
	Completed	10 (40.0)

Study: KEYNOTE 158[a]		**Pembrolizumab**
Visit	**EQ-5D-3L**	**N[b] = 25 n (%)**
	Compliance (% in those expected to complete questionnaires)[d]	10 (100.0)
Week 99	Missing by Design	16 (64.0)
	Discontinued due to adverse event	2 (8.0)
	Discontinued due to clinical progression	1 (4.0)
	Discontinued due to complete response	1 (4.0)
	Discontinued due to progressive disease	5 (20.0)
	Discontinued due to withdrawal by subject	1 (4.0)
	Completed study treatment	0 (0.0)
	Visit not reached	6 (24.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	9 (36.0)
	Not completed	2 (8.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	1 (4.0)
	Subject refused for other reasons	0 (0.0)
	Other	1 (4.0)
	With visit, no record	0 (0.0)
	Completed	7 (28.0)
	Compliance (% in those expected to complete questionnaires)[d]	7 (77.8)
Week 111	Missing by Design	18 (72.0)
	Discontinued due to adverse event	2 (8.0)
	Discontinued due to clinical progression	1 (4.0)
	Discontinued due to complete response	1 (4.0)
	Discontinued due to progressive disease	5 (20.0)
	Discontinued due to withdrawal by subject	1 (4.0)
	Completed study treatment	2 (8.0)
	Visit not reached	6 (24.0)
	Visit not scheduled	0 (0.0)
	Expected to Complete Questionnaires[c]	7 (28.0)
	Not completed	0 (0.0)
	Subject did not complete due to disease under study	0 (0.0)
	Not completed due to site staff error	0 (0.0)
	Subject refused for other reasons	0 (0.0)
	Other	0 (0.0)
	With visit, no record	0 (0.0)
	Completed	7 (28.0)
	Compliance (% in those expected to complete questionnaires)[d]	7 (100.0)

a: Database Cutoff Date: 05OCT2020

b: Number of participants: full-analysis-set population with MSI-H small intestine carcinoma, at least one line of prior therapy

c: Expected to complete questionnaire includes all participants who do not have missing data due to a missing by design reason

d: Compliance is the proportion of participants who completed the PRO questionnaire among those who are expected to complete the questionnaire at each time point, excluding those missing by design. All the other percentages are defined as the proportion of participants in the analysis population (N)

EQ-5D-3L: 3-level version of the EuroQol-5 Dimension of health questionnaire; MSI-H: Microsatellite Instability-High; PRO: Patient Reported Outcome

Anhang 4-G2: Definition der Immunvermittelten unerwünschten Ereignisse (AEOSI) anhand der zugeordneten PT

Die Definitionen der Immunvermittelten unerwünschten Ereignisse (AEOSI) anhand der zugeordneten PT in der Studie KEYNOTE 158 sind Anhang 4-G des Moduls 4 C (Magenkarzinom) zu entnehmen.